Moyamoya Disease Clinical Trials and Treatments

Moyamoya Disease is a progressive, noninflamatory cerebrovascular disease causing stenosis (narrowing) of the terminal portions of the internal carotid arteries and their major branches. In response to this narrowing, the body develops abnormal collateral vessels at the base of the brain that create the characteristic 'puff of smoke' appearance on cerebral angiography. These collateral vessels are fragile and prone to rupture.

The most common symptoms of Moyamoya Disease include Transient ischemic attacks (TIAs) with temporary weakness or numbness, Ischemic stroke causing sudden weakness, numbness, speech difficulties, or vision loss, Recurrent headaches, Seizures, Involuntary movements or tremors, among others. Higher incidence in East Asian populations (1 in 10,000 in Japan), estimated at 0.54-10.5 per 100,000 in East Asia and 0.086 per 100,000 in North America. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Moyamoya Disease from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Research in Moyamoya Disease centers on optimizing surgical approaches for revascularization while simultaneously exploring medical and neuroprotective strategies to prevent both ischemic and hemorrhagic complications. Researchers are examining how antiplatelet therapy and anticoagulation might reduce stroke risk, and newer interventions are being tested to promote healthy collateral vessel development and stabilization.

As of October 21, 2026, no current FDA drug label names Moyamoya Disease as a condition the drug treats.

The exact cause of Moyamoya Disease is not fully understood. It is not caused by a single gene; inherited variants raise risk, and immune, environmental or other triggers are thought to set it off. An RNF213 susceptibility variant is common in East Asian patients, but penetrance is reduced and most carriers never develop the disease, so there is no diagnostic gene test. Higher incidence in East Asian populations (1 in 10,000 in Japan), estimated at 0.54-10.5 per 100,000 in East Asia and 0.086 per 100,000 in North America. Research is ongoing to better understand the disease mechanism.

No single gene test diagnoses Moyamoya Disease. The diagnosis rests on clinical findings and laboratory or imaging results; genetic variants shift risk rather than cause the disease. An RNF213 susceptibility variant is common in East Asian patients, but penetrance is reduced and most carriers never develop the disease, so there is no diagnostic gene test.

Some trials collect genetic samples for research or check specific risk markers. The Genetic Testing section of this page shows any tests listed in the NIH Genetic Testing Registry, which for this condition are usually research or risk-marker tests rather than diagnostic ones.

Eligibility for Moyamoya Disease clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Moyamoya Disease clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.